iifl-logo

Mankind Pharma Ltd Quarterly Results

2,618.9
(-0.38%)
Aug 5, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Financials

Particulars (Rupees in Crores.)Jun-2025Mar-2025Dec-2024Sept-2024Jun-2024

Gross Sales

3,570.35

3,079.37

3,198.79

3,076.51

2,867.85

Excise Duty

0

0

0

0

0

Net Sales

3,570.35

3,079.37

3,198.79

3,076.51

2,867.85

Other Operating Income

0

0

0

0

0

Other Income

83.05

253.65

87.09

112

107.9

Total Income

3,653.4

3,333.02

3,285.88

3,188.51

2,975.75

Total Expenditure

2,723.58

2,400.52

2,382.8

2,226.47

2,196.29

PBIDT

929.82

932.5

903.08

962.04

779.46

Interest

170.65

190.54

220.93

7.1

10.84

PBDT

759.17

741.96

682.15

954.94

768.62

Depreciation

218.68

230.87

187.17

105.62

102.69

Minority Interest Before NP

0

0

0

0

0

Tax

110.94

131.51

157.76

168.13

138.64

Deferred Tax

-15.07

-45.07

-47.3

22.31

-15.78

Reported Profit After Tax

444.62

424.65

384.52

658.88

543.07

Minority Interest After NP

6.3

3.88

4.29

5.41

6.58

Net Profit after Minority Interest

438.32

420.77

380.23

653.47

536.49

Extra-ordinary Items

0

-4.34

6.65

0

4.59

Adjusted Profit After Extra-ordinary item

438.32

425.11

373.58

653.47

531.9

EPS (Unit Curr.)

10.62

10.19

9.46

16.31

13.39

Book Value (Unit Curr.)

0

0

0

0

0

Dividend (%)

100

0

0

0

0

Equity

41.26

41.26

40.06

40.06

40.06

Public Shareholding (Number)

0

0

0

0

0

Public Shareholding (%)

0

0

0

0

0

Pledged/Encumbered - No. of Shares

0

0

0

0

0

Pledged/Encumbered - % in Total Promoters Holding

0

0

0

0

0

Pledged/Encumbered - % in Total Equity

0

0

0

0

0

Non Encumbered - No. of Shares

0

0

0

0

0

Non Encumbered - % in Total Promoters Holding

0

0

0

0

0

Non Encumbered - % in Total Equity

0

0

0

0

0

PBIDTM(%)

26.04

30.28

28.23

31.27

27.17

PBDTM(%)

21.26

24.09

21.32

31.03

26.8

PATM(%)

12.45

13.79

12.02

21.41

18.93

Mankind Pharma: Related NEWS

Mankind Pharma Q1 Updates: Net profit down ~18%
1 Aug 2025|01:41 PM

The company also informed that its diluted earnings per share (EPS) slipped by 20.10% on a yearly basis to ₹10.60.

Read More
Top Stocks for Today - 01st August 2025
1 Aug 2025|08:58 AM

Here are some of the stocks that may see significant price movement today: Coal India, Mankind Pharma, Swiggy, etc.

Read More
Mankind Pharma posts mixed performance in Q4; stock slips ~4%
22 May 2025|12:15 PM

The business said that it logged a 10.70% year-on-year decline in its consolidated net profit at ₹420.80 Crore for Q4FY25.

Read More
Top Stocks for Today - 22nd May 2025
22 May 2025|06:38 AM

Here are some of the stocks that may see significant price movement today: NBCC, IndusInd Bank, Hindustan Zinc, etc.

Read More
Mankind Pharma Faces ₹183.11 Crore Tax Demand
30 Mar 2025|04:34 PM

The cumulative demand, including interest charges, is ₹183.11 crore.

Read More
Mankind Pharma Merges Three Subsidiaries
30 Mar 2025|01:33 PM

The merger took effect on March 29, 2025, after all necessary regulatory approvals were obtained.

Read More
Mankind Pharma Faces ₹111.68 Crore Tax Demand, Plans to Appeal
28 Feb 2025|11:13 PM

The tax adjustments pertain to Section 80IC/80IE, which involves deductions for businesses in special economic zones, and a disallowance of certain expenditures under Section 37(1) of the Act.

Read More
Top Stocks for Today - 24th January 2025
24 Jan 2025|07:50 AM

Here are some of the stocks that may see significant price movement today: Indus Towers, Dr Reddy’s Laboratories, Mankind Pharma, etc.

Read More
Mankind Pharma Q3 Profit Falls 16%, Revenue Jumps 24%
23 Jan 2025|11:57 PM

The company reported a good growth in EBITDA of 36.8% to ₹830 crore in the quarter against ₹606.5 crore in Q3 FY24.

Read More
Mankind Pharma Secures ₹5,000 Crore NCDs by Pledging 56.31% Stake in BSV
8 Jan 2025|04:01 PM

The NCDs issued are categorized, rated, secured, redeemable, and transferable, distributed across three series.

Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.